The newest weight loss drug approved by the FDA is Zepbound (tirzepatide), a dual GIP/GLP-1 (glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1) agonist. Zepbound was approved on Nov. 8, 2023 and is given as a once-weekly subcutaneous (under the skin) injection in ...